Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2022 Sep 18;12:15637. doi: 10.1038/s41598-022-19520-x

Osteogenesis in human periodontal ligament stem cell sheets is enhanced by the protease-activated receptor 1 (PAR1) in vivo

Tomaz Alves 1,2, Letícia M Gasparoni 2, Danilo Balzarini 2, Emmanuel Albuquerque-Souza 2,3, Victhor de Oliveira 4, Emanuel S Rovai 5, Jose da Silva 2, Aldrin Huamán-Mendoza 2, Luiz H Catalani 6, Carla R Sipert 7, Marinella Holzhausen 2,✉
PMCID: PMC9482923  PMID: 36117187

Abstract

Human periodontal ligament stem cells (PDLSCs) have been studied as a promising strategy in regenerative approaches. The protease-activated receptor 1 (PAR1) plays a key role in osteogenesis and has been shown to induce osteogenesis and increase bone formation in PDLSCs. However, little is known about its effects when activated in PDLSCs as a cell sheet construct and how it would impact bone formation as a graft in vivo. Here, PDLSCs were obtained from 3 patients. Groups were divided into control, osteogenic medium and osteogenic medium + PAR1 activation by TFLLR-NH2 peptide. Cell phenotype was determined by flow cytometry and immunofluorescence. Calcium deposition was quantified by Alizarin Red Staining. Cell sheet microstructure was analyzed through light, scanning electron microscopy and histology and transplanted to Balb/c nude mice. Immunohistochemistry for bone sialoprotein (BSP), integrin β1 and collagen type 1 and histological stains (H&E, Van Giesson, Masson’s Trichrome and Von Kossa) were performed on the ex-vivo mineralized tissue after 60 days of implantation in vivo. Ectopic bone formation was evaluated through micro-CT. PAR1 activation increased calcium deposition in vitro as well as BSP, collagen type 1 and integrin β1 protein expression and higher ectopic bone formation (micro-CT) in vivo.

Subject terms: Drug discovery, Stem cells

Introduction

Periodontal disease is a chronic inflammatory condition characterized by a dysbiotic microbiome mediated by host response patterns, which in advanced stages may result in a substantial breakdown of the tooth-supporting tissues, ultimately leading to tooth loss1. Periodontal tissue is a specialized distinctive structure composed by the alveolar bone, cementum and periodontal ligament. Damage to these structures severely compromises important biological functions, including bone remodeling, occlusal forces absorption and the masticatory function1.

Current both non-surgical and surgical treatments such as guided tissue regeneration (GTR) and guided bone regeneration (GBR) have been widely utilized in the clinical practice with the aim to eliminate the infection's primary cause and achieve regeneration, respectively. However, these treatment strategies have been shown to be ineffective in providing complete regeneration of hard and soft periodontal structures and the most common outcome is the formation of long junctional epithelium or the incomplete regeneration of the periodontal structures, and a long-term stable clinical regenerative outcome has not been yet achieved2–4.

Recently, several studies in the cell-based regenerative medicine field have been reported combining tissue engineering and stem cells5–7. The use of cell sheets is a promising therapeutic strategy that allows the use of mesenchymal stem cells in a construct that maintains interconnected cells in contact with their extracellular matrix, providing stability and allowing delivery to possible therapies8. Cell sheets utilizing PDLSCs are well known to mimetize the natural periodontal ligament environment in a regenerative state and to enhance cellular signal communications that potentially stimulate regeneration of periodontal tissues3.

The protease-activated receptor type 1 (PAR1) is a G protein-coupled cell membrane receptor that regulates several intracellular signaling pathways related to enhancement of osteogenic differentiation, increase in mineralized matrix deposition and upregulation of cementogenic gene expression as well9. PAR1 activation plays a key role in osteogenesis and bone regeneration5,10 by enhancing osteoblast proliferation and differentiation11, increasing the synthesis of osteoprotegerin (OPG) in periodontal ligament cells and reducing the inflammatory osteoclastogenesis induced by LPS12. Furthermore, PAR1 has been shown to be associated with vascular and coagulatory processes13 as well as bone formation and osteoclasts differentiation impairment at bone healing early stages in an animal model14.

Whether PAR1 shows an effect on PDLSCs in a cell sheet in vivo model is still unknown. This present study focused on investigating PAR1 activation on the PDLSCs cell sheet outcome in an in vivo model.

Results

Periodontal ligament isolated cells present a diverse phenotypic population

We isolated PDLSCs from third molars from 3 individuals (I1, I2 and I3) and characterized the cell lines by flow cytometry and immunofluorescence for PAR1 (Fig. 1A). Although all cell lines were positive for pluripotency surface markers (Fig. 1C), only I2 presented a positive phenotypic profile for OCT-4 (22%), SOX2 (13.2%), and STRO-1 (72.6%) in agreement with the literature to be considered a PDLSC lineage (Fig. 1B and Supp. 1 A,B)15. Further, I2 presented a high percentage of PAR1 positive PDLSCs (~ 100%), as observed by Flow Cytometry and Immunofluorescence (Fig. 1B,C).

Figure 1.

Figure 1

Open in a new tab

(A) Immunofluorescence, flow cytometry and alizarin red staining experiment flow. (B) Flow cytometry analysis showing the phenotypic characterization of PDLSCs for surface stemness, multipotent embryonic biomarkers (SOX2, OCT4, STRO-1) and PAR1 from three individuals (I1, I2 and I3). Unstained cells were used to set positive cell populations, p < 0.05. (C) PAR1 immunofluorescence expression in PDLSCs isolated cell lines. Images in 60X magnification. (D) Alizarin red staining for PDLSCs sheets (I2) after 14 days. Results are given as the mean ± SD. Figure (A) was created using BioRender.

The Alizarin Red staining was carried out using only the I2 isolated mesenchymal stem cell line to evaluate whether the PAR1 activation played a role in their osteogenic differentiation and calcium deposition. Here, PAR1 significantly promoted an increase in calcium deposits through ARS assay in I2 PDLSCs (Fig. 1D). This way, we proceeded to perform further experiments using only the I2 cell line.

Cell sheets characterization

We characterized PDLSC sheets by scanning electron microscopy (SEM), H&E and direct light microscopy (Fig. 2A). After 14 days of culture with the three different groups, PDLSC sheets were fully formed and ready to undergo full detachment from the dishes (Supp. 2B). Light microscopy images showed a confluent fibroblastic-like profile as expected (Fig. 2B). Furthermore, qualitative analysis of the H&E sections detected differences in cell sheet thickness degree in the OST and OST + PAR1 groups when compared with the CTRL group (Fig. 2B).

Figure 2.

Figure 2

Open in a new tab

(A) Cell sheets manufacturing and macroscopic morphological characterization workflow. (B) Light microscopy (40x), cell sheet histological profile by H&E staining and microstructural analysis through scanning electron microscopy (400x) from cell sheets for the 3 experimental groups.

PAR1 activation in PDLSCs cell sheets enhanced mineralization after in vivo transplantation

In order to evaluate the osteogenic potential of PAR1 activation in PDLSCs sheets, we performed in vivo experiments by transplanting cell sheets into the subcutaneous of Balb/c nude mice to evaluate the ectopic bone formation through micro-CT after a 60-days period (Fig. 3A). Micro-CT results were displayed in bone volume/tissue volume percentage (BV/TV %) (Fig. 3B). The OST + PAR1 group demonstrated a higher ectopic bone formation outcome in comparison with the other groups (p < 0.05) (Fig. 3B).

Figure 3.

Figure 3

Open in a new tab

(A) Cell sheets in vivo transplant and ex-vivo analysis workflow. (B) Micro-CT analysis of ectopic bone formation in vivo after 60 days of transplantation (B) and the statistical analysis comparing the BV/TV% between the 3 groups CTRL, OST and OST + PAR1. (*) means a p < 0.05 compared to control. Results are given as the mean ± SD. Figure (A) was created using BioRender.

PAR1 activation mediates osteogenesis in PDLSC sheets in vivo

Histological qualitative analysis from H&E, Masson Trichrome, Van Gieson and Von Kossa stains from the 3 groups after a 2-month transplantation period in Balb/c nude mice suggested an increased osteogenic process displayed by greater presence of osteoblast clusters and lower abundance of undifferentiated fibroblast-like cells for the OST + PAR1 group (Fig. 4A) and increased calcium deposition in the neoformed bone matrix (Fig. 4B) when compared to the OST and CTRL groups (Fig. 4A,B). Furthermore, a qualitative analysis suggested a higher number of vessels in the OST group when compared to the other groups, suggesting that this group was in an intermediate osteogenesis stage when compared to the OST + PAR1 group (Fig. 4A).

Figure 4.

Figure 4

Open in a new tab

(A) Ex-vivo histological qualitative analysis from H&E, Van Gieson, Masson’s Trichrome and Von Kossa stains from the 3 groups after a 2-month transplantation period in balb/c nude mice. Images at 10x and 20x. CTRL group displayed connective tissue characteristics with necrotic spots (gray arrows) and no bone formation was detected in this group for the 4 stains. Osteoblast clusters (black solid arrows) and blood vessels (red solid arrows) were detected in higher abundance in the OST group when compared with the other groups. The OST + PAR1 group showed greater osteocyte numbers (black dotted circle) and higher calcium deposits (B) (red dotted line).

PAR1-induced mineralization in vivo is followed by an upregulation of osteogenic markers

Immunohistochemistry results presented a higher positive expression of BSP in the OST + PAR1 group when compared with the other groups (Fig. 5A,B). Moreover, the expression of integrin 1β and collagen type 1 was detected in higher levels at the OST + PAR1 group when compared with the other groups (Fig. 5A,B).

Figure 5.

Figure 5

Open in a new tab

(A) Histological immunohistochemistry quantification analysis for collagen type I, integrin 1β and bone sialoprotein for the 3 groups ex-vivo samples after a 2-month transplantation period in balb/c nude mice. (B) A semi-quantification analysis was performed for the 3 protein markers and the PAR1 activation group showed greater staining for the 3 osteogenic protein markers after 60 days. Images at 10x. (*) p < 0.05. Results are given as the mean ± SD.

Discussion

In this study, we investigated the osteogenic potential of the PAR1 activation by using a cell sheet engineering strategy in an in vivo model. Previous studies have reported the role of PAR1 in the osteogenic processes demonstrating that its absence is associated with derived bone marrow cells migration impairment, an increase in osteoclast colonization, enhanced osteoclastogenesis and a decrease in mineralized bone deposition in vivo14,16.

On the other hand, PAR1 activation has been largely reported to upregulate bone formation by mediating proliferative responses in osteoblasts5,10,14. Our group has previously demonstrated that PAR1 activation in PDLSCs is specifically associated with an increase in mineralized nodule deposition, higher calcium concentration levels and increased PDLSC proliferation. In addition, PAR1 blockage decreased the calcium deposition, suggesting that PAR1 plays a major role in mineralization and differentiation of PDLSCs17.

In the present study, we isolated PDLSCs from three patients, characterized the surface marker phenotypes by flow cytometry and purposefully proceeded to evaluate the osteogenic differentiation potential in the cell line that presented a mesenchymal profile (I2). The non-specialized mesenchymal stem cells found in the periodontal ligament tissue, such as PDLSCs present pluripotency properties that allow differentiation into several cell types, including osteoblasts and cementoblasts. These cells exhibit a phenotype that is compatible with the positive expression of OCT4, STRO-1, CD-44 and CD-146 cell markers18–22. Further, cells with positive expression of STRO-1 were found to be related to periodontal tissue formation and expressed in dental follicle cells in mice23,24.

Our results demonstrated a possible correlation between the presence of stemness markers (OCT4, CD146, SOX2, CD-90, STRO-1, CD-44) and PAR1 prevalence, with a higher calcium deposition being found in I2 in the ARS essay, although further analysis is needed to confirm this association. At the same time, I2 was negative for CD14, CD31, and CD34, corroborating with PDLSCs phenotype present in the literature15.

Vascularization is a key mechanism in the earliest stages of osteogenesis during ectopic bone formation25,26 and angiogenesis is pivotal to enabling osteogenesis in vivo27. The absence of vascularization leads to tissue necrosis through hypoxia and nutrients dearth28–30. Cell sheets present improved vessel formation capability because the space between the cell layers allows for the formation of capillaries and, therefore, vascularization in newly transplanted grafts31.

In this study, we could identify qualitative histological differences between the groups regarding angiogenesis. The CTRL group exhibited a significant number of white spots suggesting necrotic areas, possibly due to a lack of vessel formation (Fig. 4A), especially when compared with the OST and OST + PAR1 groups (Fig. 4A). These findings could be explained by the absence of ascorbic acid in the CTRL group, in which depletion is related to angiogenesis impairment by inhibiting mature type IV collagen formation32. Further, the possible vascularization found in the OST group (Fig. 4A) may be explained since the group was at an earlier stage of osteogenesis when compared to the OST + PAR1 group, suggesting that the osteogenesis process may have been “accelerated” by PAR1 activation, which is also known to play a role in angiogenesis33–35 and coagulatory pathways13. These findings corroborate with several studies that demonstrated the pro-angiogenic role of PAR1 activation mainly through VEGF increased expression33–35. Further, VEGF has been shown to be an important angiogenic marker on studies evaluating the osteogenic and osteointegration processes on PDLSCs exposed to titanium-derived biomaterials in vitro36,37.

In fact, the enhanced osteogenic profile found in the OST + PAR1 group on the histological findings was consistent with the immunohistochemistry and micro-CT results in our study (Fig. 3). Evaluation of bone volume percentage (BV/TV %) through micro-CT displayed significantly higher values in the OST + PAR1 group when compared to the OST and CTRL groups (Fig. 3B).

In the bone neoformation processes, several extracellular molecules produced by differentiating osteogenic cells can be used to identify the stages of bone maturation in vivo38. Integrin 1β functions as a modulator, facilitating osteoblast attachment, spreading, adhesion, migration, and differentiation in osteogenesis via specific alpha(v)beta(3) signaling pathway39,40 and is capable of recognizing ligands with RGD-motifs, like BSP, which works as an osteoblast differentiation marker expressed during initial stages of bone formation41,42. Further, integrin 1β is capable of promoting angiogenesis by mediating human endothelial cell attachment and migration40 and is found to be able to integrate complexes that functions as a receptor to several collagen types43. In this matter, PAR1 activation is intrinsically related to an increase in collagen deposition in fibroblasts44,45 and, therefore, enhancing adhesion when integrin β1 is present in the substrate46,47.

In this study, the immunohistochemistry assay results for the OST + PAR1 group showed a higher protein expression for collagen type I, integrin 1β and BSP comparing with the other groups, evidencing an upregulated expression of important osteogenic immunological markers mediated by the PAR1 activation.

Finally, it is important to highlight some limitations present in this study. First, the research included only one donor cell line for the main experiments, which substantially reduces the external validity of the in vitro findings. Secondly, we found great difficulty in isolating mesenchymal strains from patients and a great difference in the surface markers characterization was found among the isolated cells. Moreover, although the flow cytometry data from the Individual 2 isolated cells were positive for a panel of surface and transcriptional factors of stemness, further differentiation into other mesenchymal cell types, i.e., adipocytes and chondrocytes, would be necessary to fully confirm their pluripotency phenotype. Yet, the osteoblastic differentiation verified in the present study suggests the therapeutic applicability in bone regeneration for PDLSCs presenting the herein characterized immunophenotyping profile. Finally, PAR1 expression was found to be widely variable, limiting the receptor activation associated outcomes for further PAR1 targeting therapies.

On the other hand, the use of cell sheets obtained through the removal of third molars seems to be a feasible option for further clinical therapies, since cell sheets present no associated adverse reactions because they can be obtained from and implanted in the same donor. Moreover, cell sheets are feasible to be used in regeneration procedures because the preservation of the extracellular matrix provides good structural stability and manageability, allowing this tissue engineering strategy to have a promising future as an option in regenerative treatments.

The main finding of this study is that the PAR1 activation in PDLSCs cell sheets enhanced osteogenesis in vivo. In addition, in vitro results from ARS reinforced that the presence of cell phenotype for stemness and PAR1 surface biomarkers are associated with an upregulation of osteogenesis in PDLSCs.

Methods

We confirm that all methods were carried out in accordance with ARRIVE guidelines and relevant guidelines and regulations.

Ethics Statement

Informed consent was obtained from all subjects and the ethical committee approval from the Ethics Committee Review Board at the School of Dentistry of the University of São Paulo (FO-USP-protocol number 029/2018) was obtained prior to the patient's teeth collection at the clinic of the School of Dentistry of the University of São Paulo (FO-USP). The utilization of Balb/c nude mice in this research was also approved by the Ethics Committee on Animal Use (CEUA) board at the Chemistry Institute of the University of Sao Paulo (IQ-USP) under the protocol number 98/2018.

Cells isolation

Periodontal ligament stem cells were harvested from third molars from 3 systemically healthy individuals (I1, I2 and I3—18 to 30 years old). The inclusion criteria were: partially or totally erupted third molars and absence of periodontal disease.

Periodontal ligament tissue specimens were obtained through the scaling of the middle third of the root and PDLSCs were isolated using the explant technique12,48 in alpha-modified Eagle’s medium (α-MEM) (Thermo Fisher Scientific, Waltham, USA) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Waltham, USA), 100 μg/mL penicillin, 100 μg/mL streptomycin, and 0.5 mg/mL amphotericin B (Gibco, Invitrogen, Carlsbad, USA) at 37 °C in an atmosphere of 5% CO2 and 95% humidity7. After 14 days, cells from the explants achieved a 70% confluence degree and PDLSCs populations were used in passage 4 for all experiments.

Pluripotency characterization

In order to identify the mesenchymal stem cell phenotype, approximately 5 × 105 PDLSCs were incubated in 5% bovine serum albumin (BSA)/phosphate buffered saline (PBS) (Gibco, Invitrogen, Carlsbad, USA) 1 × at 4 °C in dark for 1 h with the following monoclonal antibodies: PAR1-FITC (Abcam, Cambridge, UK), OCT4-FITC (Abcam, Cambridge, UK), SOX2-FITC (Abcam, Cambridge, UK), STRO-1-FITC (Abcam, Cambridge, UK), CD14-FITC (eBioscience, San Diego, USA), CD90-FITC (eBioscience, San Diego, USA), CD31-PE (eBioscience, San Diego, USA), CD-44-PE (eBioscience, San Diego, USA), CD34-FITC (Biolegend, San Diego, USA) and CD146-PE (Biolegend, San Diego, USA) for 30 min at 4 °C. Unstained control was used to set gates. A total of 10–50,000 events were recorded and data analyzed through FlowJo (Becton Dickinson, Oregon, USA).

Cell sheet culture and experimental design

PDLSCs at 1 × 106 cells/cm2 were seeded in 100 mm plates for 24 h with α-MEM (Thermo Fisher Scientific, Waltham, USA) supplemented with 10% of FBS (Thermo Fisher Scientific, Waltham, USA) and 50 μg/mL vitamin C to induce cell sheet formation, as previously described7. Subsequently, cell sheets were assigned for one of the following experimental groups: (1) control medium (CTRL) composed of α-MEM (Thermo Fisher Scientific, Waltham, USA) supplemented with 10% of FBS (Thermo Fisher Scientific, Waltham, USA) and 50 μg/mL vitamin C (Sigma-Aldrich, St Louis, USA); (2) osteogenic medium (OST) (CTRL + 100 nM dexamethasone, 5 mM b-glycerophosphate and 50 µg/ml ascorbic acid (Sigma-Aldrich, St Louis, USA) and (3) osteogenic medium with the addition the PAR1 agonist peptide (100 nM TFLLR-NH2) (Tocris Bioscience Inc., Bristol, UK) (OST + PAR1). The culture medium was changed every 3 days for 14 days.

Alizarin red staining

The PDLSCs from I2 were seeded in 6-well plates (5 × 104 cells/cm2), in triplicate. After treatment with CTRL, OST and OST + PAR1 groups for 14 days, cell sheets were washed with 1 × PBS (Sigma-Aldrich, St Louis, USA), fixed with 4% paraformaldehyde (Sigma-Aldrich, St Louis, USA) for 15 min at room temperature (RT), washed with 1 × PBS (Sigma-Aldrich, St Louis, USA) again and incubated with a stirring solution of 2% Alizarin Red S (Sigma-Aldrich, St Louis, USA) in PBS (Sigma-Aldrich, St Louis, USA) (pH 4.2) (A5533) for 30 min at RT. For qualitative and macroscopic analysis, images were acquired using a microscope CDD camera (D7000, Nikon, Minato, Japan). For the quantitative analysis, 10% ammonium hydroxide (Sigma-Aldrich, St Louis, USA) solution was used to dilute calcium deposits and a spectrophotometer (Biotek, Winooski, USA) was used to measure the absorbance at 405 nm. ARS quantification was calculated using a standard-curve.

Cell sheet characterization

Scanning electron microscopy

Cell sheets at 14-days treatment were fixed with Karnovsky's solution (Thermo Fisher Scientific, Waltham, USA) for 24 h. After this period, post-fixation was performed with osmium tetroxide (Sigma-Aldrich, St Louis, USA) for 2 h and dehydration, passing the material through an increasing series of alcohol (Sigma-Aldrich, St Louis, USA) from 70 to 100%. The samples were further dried under critical point conditions and sputter coated with gold. Observations were then performed by using a scanning electron microscope (S-4800; Hitachi, Tokyo, Japan).

Histological profile

Hematoxylin and eosin (Sigma-Aldrich, St Louis, USA) staining of cell sheets was also performed. Briefly, after detachment and fixation in 4% paraformaldehyde (Sigma-Aldrich, St Louis, USA) for 24 h, samples were paraffin embedded and sectioned in 4 µm thickness. After the sectioning process, the histological samples were placed in a water bath at 50 °C and captured to a histological slide and stored in an oven at 65 °C for 12 h to allow the paraffin remnants to be removed. Sequentially, paraffin removal dehydration protocol was completed using a sequence of xylol (Sigma-Aldrich, St Louis, USA) and alcohol (Sigma-Aldrich, St Louis, USA) solutions and the specimens proceeded a routine H&E staining following the manufacturer's guidelines.

Ectopic bone formation assays

In vivo bone formation was evaluated using transplantation of cell sheets pre-incubated with the experimental groups described above. At 14 days of incubation, cell sheets were detached using a cell scraper (Corning, New York, USA), folded 4 times to acquire a cylinder shape and each 6-weeks old Balb/c nude mice received 2 dorsal transplants from the same experimental group, bilaterally. In total, 25 mice were distributed to the groups as follows: 11 (OST + PAR1), 11 (OST) and 3 (CTRL). After 60 days, mice were euthanized and the subcutaneous samples were removed and processed for the analysis described below.

Computerized microtomography

After fixation, only the left side subcutaneous sample from each animal was scanned using a micro-CT system (Skyscan 1176, Bruker Biospin, Billerica, USA) with the following acquisition parameters: 45 kV, 8.71 μm resolution and 550 μA. Data obtained were processed, reconstructed into three-dimensional images using a reconstruction software (NRecon, Micro Photonics, Allentown, USA) and analyzed using a system software (CTAn, Bruker Biospin, Billerica, USA).

Immunohistochemistry and histological analysis

Histological procedures were performed as described previously. H&E, Masson’s Trichrome, Van Gieson and Von Kossa stains (Sigma-Aldrich, St Louis, USA) were carried out following the manufacturer’s protocol. For immunohistochemistry analysis, after fixation in a 4% paraformaldehyde solution in PBS for 30 min, the samples were embedded in paraffin and sectioned at 20 µm. Cuts were subjected to dewaxing, rehydration, and permeabilized with 0.2% Triton X-100 (Sigma-Aldrich, St Louis, USA) for 10 min. Then, the sections were blocked in 3% hydrogen peroxide solution (Sigma-Aldrich, St Louis, USA) for 10 min followed by antigen retrieval with 10% citrate buffer (Sigma-Aldrich, St Louis, USA) for 15 min and blockage in 5% BSA (Sigma-Aldrich, St Louis, USA) for another 30 min. Then, exposure to the specific primary antibodies was performed for: β1 integrin—AB52971 (Abcam, Cambridge, UK), type I collagen—AB34710 (Abcam, Cambridge, UK), and BSP—AB8448 (Abcam, Cambridge, UK). The slides were then incubated with a secondary conjugated anti-rabbit IgG antibody—AB205718 (Abcam, Cambridge, UK) followed by an avidin-biotin complex (Abcam, Cambridge, UK) incubation for 30 min. The diaminobenzidine (DAB) solution (Abcam, Cambridge, UK) was applied every 2 min and the reaction was observed in a microscope. Specimens were dehydrated, cleared and mounted. Images from the specimens were obtained with a light microscope (E600, Nikon, Tokyo, Japan) and three images of each sample were acquired and quantified using Image J (NIH, Bethesda, USA).

Statistical analysis

Experiments were performed in triplicate and data were expressed as means ± standard deviation (SD). Data were analyzed based on the comparison between the experimental group (OST + PAR1) with the osteogenic control group (OST) and the control (CTRL). One-way ANOVA followed with post-hoc Tukey’s test was used. A significance P value of 0.05 was established for all tests and the data analysis was performed (GraphPad Prism™ Version 6.0c, La Jolla, USA).

Supplementary Information

Supplementary Information. (52.7MB, pdf)

Acknowledgements

This work was supported by the São Paulo Research Foundation (FAPESP) grants 2017/23158-0 and 2018/13818-5, the Coordination for the Improvement of Higher Education Personnel—(CAPES) Finance code 001 and the J. William Fulbright scholarship. Figures were produced using BioRender.

Author contributions

T.A., L.M.G., E.A. and M.H. conceived and designed the experiments; T.A., L.M.G., D.B., V.O., J.S., and A.H. performed the experimental work and contributed to the manipulation of materials, reagents, and analysis tools; T.A., D.B., and J.S. performed animal experiments; T.A. and E.A., analyzed the data and wrote the manuscript. T.A. drafted the major portion of the manuscript and M.H., E.A., E.S.R., L.H.C. and C.R.S. contributed with major revisions. T.A., M.H., E.S.R. and A.H. contributed with the final revisions. T.A. and L.M.G. structured the figures. All authors read and approved the final manuscript.

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-022-19520-x.

References

  • 1.Caton G, J., et al. A new classification scheme for periodontal and peri-implant diseases and conditions—Introduction and key changes from the 1999 classification. J. Clin. Periodontol. 2018;45:S1–S8. doi: 10.1111/jcpe.12935. [DOI] [PubMed] [Google Scholar]
  • 2.Magnusson I, Runstad L, Nyman S, Lindhe J. A long junctional epithelium–A locus minoris resistentiae in plaque infection? J. Clin. Periodontol. 1983;10:333–340. doi: 10.1111/j.1600-051X.1983.tb01282.x. [DOI] [PubMed] [Google Scholar]
  • 3.Gao LN, et al. The effect of the coumarin-like derivative osthole on the osteogenic properties of human periodontal ligament and jaw bone marrow mesenchymal stem cell sheets. Biomaterials. 2013;34:9937–9951. doi: 10.1016/j.biomaterials.2013.09.017. [DOI] [PubMed] [Google Scholar]
  • 4.Kim K, Utoh R, Ohashi K, Kikuchi T, Okano T. Fabrication of functional 3D hepatic tissues with polarized hepatocytes by stacking endothelial cell sheets in vitro. J. Tissue Eng. Regen. Med. 2017;11:2071–2080. doi: 10.1002/term.2102. [DOI] [PubMed] [Google Scholar]
  • 5.Mackie EJ, et al. Protease-activated receptors in the musculoskeletal system. Int. J. Biochem. Cell Biol. 2008;40:1169–1184. doi: 10.1016/j.biocel.2007.12.003. [DOI] [PubMed] [Google Scholar]
  • 6.Ramachandran R, Altier C, Oikonomopoulou K, Hollenberg MD. Proteinases, their extracellular targets, and inflammatory signaling. Pharmacol. Rev. 2016;68:1110–1142. doi: 10.1124/pr.115.010991. [DOI] [PubMed] [Google Scholar]
  • 7.Mendoza AH, Balzarini D, Alves T, Rovai ES, Holzhausen M. Potential of mesenchymal stem cell sheets on periodontal regeneration: A systematic review of pre-clinical studies. Syst. Rev. Article. 2022 doi: 10.2174/1574888x17666220706092520. [DOI] [PubMed] [Google Scholar]
  • 8.Kim J-H, et al. Tumor necrosis factor-alpha antagonist diminishes osteocytic RANKL and sclerostin expression in diabetes rats with periodontitis. PLoS ONE. 2017;12:e0189702. doi: 10.1371/journal.pone.0189702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Rovai ES, et al. Protease-activated receptor type 1 (PAR1) increases CEMP1 gene expression through MAPK/ERK pathway. Braz. Oral Res. 2022;36:1–8. doi: 10.1590/1807-3107bor-2022.vol36.0048. [DOI] [PubMed] [Google Scholar]
  • 10.Sato N, et al. Thrombin induced by the extrinsic pathway and PAR1 regulated inflammation at the site of fracture repair. Bone. 2016;83:23–34. doi: 10.1016/j.bone.2015.10.005. [DOI] [PubMed] [Google Scholar]
  • 11.Abraham LA, Mackie EJ. Modulation of osteoblast-like cell behavior by activation of protease-activated receptor-1. J. Bone Miner. Res. 1999;14:1320–1329. doi: 10.1359/jbmr.1999.14.8.1320. [DOI] [PubMed] [Google Scholar]
  • 12.Arayatrakoollikit U, Pavasant P, Yongchaitrakul T. Thrombin induces osteoprotegerin synthesis via phosphatidylinositol 3′-kinase/mammalian target of rapamycin pathway in human periodontal ligament cells. J. Periodontal Res. 2008;43:537–543. doi: 10.1111/j.1600-0765.2007.01071.x. [DOI] [PubMed] [Google Scholar]
  • 13.Rovai ES, Alves T, Holzhausen M. Protease-activated receptor 1 as a potential therapeutic target for COVID-19. Exp. Biol. Med. 2021;246:688–694. doi: 10.1177/1535370220978372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Song SJ, Pagel CN, Campbell TM, Pike RN, Mackie EJ. The role of protease-activated receptor-1 in bone healing. Am. J. Pathol. 2005;166:857–868. doi: 10.1016/S0002-9440(10)62306-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Choi JK, Hwang HI, Jang YJ. The efficiency of the in vitro osteo/dentinogenic differentiationof human dental pulp cells, periodontal ligament cellsand gingival fibroblasts. Int. J. Mol. Med. 2015;35:161–168. doi: 10.3892/ijmm.2014.1986. [DOI] [PubMed] [Google Scholar]
  • 16.Jastrzebski S, et al. Protease-activated receptor 1 deletion Causes enhanced osteoclastogenesis in response to inflammatory signals through a notch2-dependent mechanism. J. Immunol. 2019;203:105–116. doi: 10.4049/jimmunol.1801032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Rovai ES, et al. Protease-activated receptor type 1 activation enhances osteogenic activity in human periodontal ligament stem cells. Stem Cells Int. 2019;2019:6857386. doi: 10.1155/2019/6857386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Xu J, Wang W, Kapila Y, Lotz J, Kapila S. Multiple differentiation capacity of STRO-1 +/CD146 + PDL mesenchymal progenitor cells. Stem Cells Dev. 2009;18:487–496. doi: 10.1089/scd.2008.0113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Fujii S, et al. Investigating a clonal human periodontal ligament progenitor/stem cell line in vitro and in vivo. J. Cell. Physiol. 2008;215:743–749. doi: 10.1002/jcp.21359. [DOI] [PubMed] [Google Scholar]
  • 20.Gay IC, Chen S, MacDougall M. Isolation and characterization of multipotent human periodontal ligament stem cells. Orthod. Craniofacial Res. 2007;10:149–160. doi: 10.1111/j.1601-6343.2007.00399.x. [DOI] [PubMed] [Google Scholar]
  • 21.Nagatomo K, et al. Stem cell properties of human periodontal ligament cells. J. Periodontal Res. 2006;41:303–310. doi: 10.1111/j.1600-0765.2006.00870.x. [DOI] [PubMed] [Google Scholar]
  • 22.Chen SC, Marino V, Gronthos S, Bartold PM. Location of putative stem cells in human periodontal ligament. J. Periodontal Res. 2006;41:547–553. doi: 10.1111/j.1600-0765.2006.00904.x. [DOI] [PubMed] [Google Scholar]
  • 23.Kémoun P, et al. Localization of STRO-1, BMP-2/-3/-7, BMP receptors and phosphorylated Smad-1 during the formation of mouse periodontium. Tissue Cell. 2007;39:257–266. doi: 10.1016/j.tice.2007.06.001. [DOI] [PubMed] [Google Scholar]
  • 24.Kémoun P, et al. Human dental follicle cells acquire cementoblast features under stimulation by BMP-2/-7 and enamel matrix derivatives (EMD) in vitro. Cell Tissue Res. 2007;329:283–294. doi: 10.1007/s00441-007-0397-3. [DOI] [PubMed] [Google Scholar]
  • 25.Gerber HP, Ferrara N. Angiogenesis and bone growth. Trends Cardiovasc. Med. 2000;10:223–228. doi: 10.1016/S1050-1738(00)00074-8. [DOI] [PubMed] [Google Scholar]
  • 26.Bragdon B, et al. Earliest phases of chondrogenesis are dependent upon angiogenesis during ectopic bone formation in mice. Bone. 2017;101:49–61. doi: 10.1016/j.bone.2017.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Amini AR, Laurencin CT, Nukavarapu SP. Bone tissue engineering: Recent advances and challenges. Crit. Rev. Biomed. Eng. 2012;40:363–408. doi: 10.1615/CritRevBiomedEng.v40.i5.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Novosel EC, Kleinhans C, Kluger PJ. Vascularization is the key challenge in tissue engineering. Adv. Drug Deliv. Rev. 2011;63:300–311. doi: 10.1016/j.addr.2011.03.004. [DOI] [PubMed] [Google Scholar]
  • 29.Phelps EA, García AJ. Engineering more than a cell: Vascularization strategies in tissue engineering. Curr. Opin. Biotechnol. 2010;21:704–709. doi: 10.1016/j.copbio.2010.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.L, R. et al. Preparation of three-dimensional vascularized msc cell sheet constructs for tissue regeneration. Biomed Res. Int.2014, (2014). [DOI] [PMC free article] [PubMed]
  • 31.Sakaguchi K, Shimizu T, Okano T. Construction of three-dimensional vascularized cardiac tissue with cell sheet engineering. J. Control. Release. 2015;205:83–88. doi: 10.1016/j.jconrel.2014.12.016. [DOI] [PubMed] [Google Scholar]
  • 32.Telang S, Clem AL, Eaton JW, Chesney J. Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. Neoplasia. 2007;9:47–56. doi: 10.1593/neo.06664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ma L, et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl. Acad. Sci. USA. 2005;102:216–220. doi: 10.1073/pnas.0406682102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Yin Y, et al. Oncogenic transformation induces tumor angiogenesis: A role for PAR1 activation. FASEB J. 2003;17:163–174. doi: 10.1096/fj.02-0316com. [DOI] [PubMed] [Google Scholar]
  • 35.Hu S, Wu G, Zheng J, Liu X, Zhang Y. Astrocytic thrombin-evoked VEGF release is dependent on p44/42 MAPKs and PAR1. Biochem. Biophys. Res. Commun. 2019;509:585–589. doi: 10.1016/j.bbrc.2018.12.168. [DOI] [PubMed] [Google Scholar]
  • 36.Diomede F, et al. VEGF/VEGF-R/RUNX2 Upregulation in human periodontal ligament stem cells seeded on dual acid etched titanium disk. Materials (Basel). 2020;13(3):706. doi: 10.3390/ma13030706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Marconi GD, et al. Enhanced VEGF/VEGF-R and RUNX2 Expression in human periodontal ligament stem cells cultured on sandblasted/etched titanium disk. Front. Cell Dev. Biol. 2020;8:315. doi: 10.3389/fcell.2020.00315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lekic P, Sodek J, McCulloch CAG. Osteopontin and bone sialoprotein expression in regenerating rat periodontal ligament and alveolar bone. Anat. Rec. 1996;244:50–58. doi: 10.1002/(SICI)1097-0185(199601)244:1&#x0003c;50::AID-AR5&#x0003e;3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  • 39.Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol. 2011;3:1–14. doi: 10.1101/cshperspect.a004994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Bellahcène A, et al. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ. Res. 2000;86:885–891. doi: 10.1161/01.RES.86.8.885. [DOI] [PubMed] [Google Scholar]
  • 41.Marom R, Shur I, Solomon R, Benayahu D. Characterization of adhesion and differentiation markers of osteogenic marrow stromal cells. J. Cell. Physiol. 2005;202:41–48. doi: 10.1002/jcp.20109. [DOI] [PubMed] [Google Scholar]
  • 42.Harris NL, et al. Functional analysis of bone sialoprotein: Identification of the hydroxyapatite-nucleating and cell-binding domains by recombinant peptide expression and site-directed mutagenesis. Bone. 2000;27:795–802. doi: 10.1016/S8756-3282(00)00392-6. [DOI] [PubMed] [Google Scholar]
  • 43.Leitinger B, Hohenester E. Mammalian collagen receptors. Matrix Biol. 2007;26:146–155. doi: 10.1016/j.matbio.2006.10.007. [DOI] [PubMed] [Google Scholar]
  • 44.Fiorucci S, et al. PAR1 Antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology. 2004;39:365–375. doi: 10.1002/hep.20054. [DOI] [PubMed] [Google Scholar]
  • 45.Shi G, et al. Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling. Biochem. Biophys. Res. Commun. 2018;500:550–556. doi: 10.1016/j.bbrc.2018.04.071. [DOI] [PubMed] [Google Scholar]
  • 46.Kanemaru M, Maehara N, Iwamura T, Chijiiwa K. Thrombin stimulates integrin β1-dependent adhesion of human pancreatic cancer cells to vitronectin through protease-activated receptor (PAR)-1. Hepatogastroenterology. 2012;59:1614–1620. doi: 10.5754/hge10036. [DOI] [PubMed] [Google Scholar]
  • 47.Rudroff C, Striegler S, Schilli M, Scheele J. Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1. Eur. J. Surg. Oncol. 2001;27:472–476. doi: 10.1053/ejso.2001.1141. [DOI] [PubMed] [Google Scholar]
  • 48.Somerman MJ, Archer SY, Imm GR, Foster RA. A comparative study of human periodontal ligament cells and gingival fibroblasts in vitro. J. Dent. Res. 1988;67:66–70. doi: 10.1177/00220345880670011301. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information. (52.7MB, pdf)

Data Availability Statement

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES